MoonLake Immunotherapeutics (MLTX) Cash Flow Statement
MoonLake Immunotherapeutics (MLTX) generated -$225.2M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$225.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MLTXMoonLake ImmunotherapeuticsFollow MLTX — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.6 | -55.9 | -42.8 | -116.6 | -196.0 | -225.2 | |
| Capital expenditure | — | 0.0 | 0.3 | 0.5 | 0.0 | -0.0 | |
| Free cash flow | — | -55.9 | -43.1 | -117.1 | -196.0 | -225.2 | |
| Share repurchases | — | — | — | 0.0 | — | — | |
| Stock-based compensation | — | 9.7 | 7.1 | 7.3 | 12.9 | — |
USD millions · SEC XBRL
MoonLake Immunotherapeutics — questions
- What is MoonLake Immunotherapeutics's operating cash flow?
- -$225.2M over the twelve months to 2026-06-30.
- How much does MoonLake Immunotherapeutics spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is MoonLake Immunotherapeutics's free cash flow?
- -$225.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from MoonLake Immunotherapeutics's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.